CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

UCB

UCBJY
$57.07B
Large Cap
NASDAQHealthcare🇺🇸North America8.6K employees

Drugs in Pipeline

92

Phase 3 Programs

65

Upcoming Catalysts

8

Next Catalyst

Feb 19, 2026

11d
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

8 upcoming, 2 past

Phase 2Next

doxecitine and doxribtimine Phase 2 Results Expected

Feb 19, 2026doxecitine and doxribtimine47

Primary completion for doxecitine and doxribtimine trial (NCT03845712) in Thymidine Kinase 2 Deficiency

Source
⭐Phase 3

Staccato alprazolam Phase 3 Results Expected

Apr 6, 2026Staccato alprazolam350

Primary completion for Staccato alprazolam trial (NCT05077904) in Stereotypical Prolonged Seizures

Source
⭐Phase 3

Bimekizumab Phase 3 Results Expected

May 25, 2026Bimekizumab1,131

Primary completion for Bimekizumab trial (NCT04009499) in Psoriatic Arthritis

Source
⭐Phase 3

zilucoplan (RA101495) Phase 3 Results Expected

Jun 2, 2026zilucoplan (RA101495)200

Primary completion for zilucoplan (RA101495) trial (NCT04225871) in Generalized Myasthenia Gravis

Source
⭐Phase 3

rozanolixizumab Phase 3 Results Expected

Jun 8, 2026Rozanolixizumab12

Primary completion for rozanolixizumab trial (NCT06149559) in Generalized Myasthenia Gravis

Source
⭐Phase 3

Bimekizumab Phase 3 Results Expected

Jul 28, 2026Bimekizumab658

Primary completion for Bimekizumab trial (NCT04436640) in Axial Spondyloarthritis

Source
⭐Phase 3

fenfluramine Phase 3 Results Expected

Sep 3, 2026fenfluramine25

Primary completion for fenfluramine trial (NCT06118255) in Dravet Syndrome

Source
⭐Phase 3

Zilucoplan Phase 3 Results Expected

Nov 16, 2026Zilucoplan8

Primary completion for Zilucoplan trial (NCT06055959) in Generalized Myasthenia Gravis

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

Adalimumab

Phase 3

Psoriatic Arthritis

Levocetirizine 1.25 mg

Phase 3

Allergic Rhinitis

Levocetirizine

Phase 3

Rhinitis, Allergic, Seasonal

Certolizumab Pegol

Phase 3

Rheumatoid Arthritis

Brivaracetam (BRV)

Phase 3

Epilepsy

Levetiracetam (LEV)

Phase 3

Epilepsy

Brivaracetam (ucb 34714)

Phase 3

Epilepsy

Staccato alprazolam

Phase 3

Stereotypical Prolonged Seizures

CZP 400 mg Q4W

Phase 3

Spondyloarthropathies

Rotigotine

Phase 3

Restless Legs Syndrome

CDP870

Phase 3

Arthritis, Rheumatoid

Brivaracetam oral solution

Phase 3

Childhood Absence Epilepsy

Brivaracetam

Phase 3

Epilepsy

Carbamazepine Controlled Release (CBZ-CR)

Phase 3

Epilepsy

Keppra XR (Levetiracetam XR)

Phase 3

Epilepsy

Carbamazepine-Controlled Release (CBZ-CR)

Phase 3

Epilepsy

Zilucoplan

Phase 3

Generalized Myasthenia Gravis

Cetirizine

Phase 3

Dermatitis

SPM 929

Phase 3

Painful Diabetic Neuropathy

e-Device

Phase 3

Moderate and Severe Active Rheumatoid Arthritis

USL261

Phase 3

Epilepsy

Certolizumab Pegol (CDP870)

Phase 3

Crohn's Disease

Alprazolam orally disintegrating tablets

Phase 3

ANXIETY

PARCOPA

Phase 3

Parkinson's Disease

Brivaracetam Film-coated tablet

Phase 3

Childhood Absence Epilepsy

Levetiracetam

Phase 3

Epilepsy

Levetiracetam 250 mg

Phase 3

Epilepsies, Partial

Carbamazepine-Controlled Release

Phase 3

Epilepsy

CZP 200 mg Q2W

Phase 3

Arthritis, Psoriatic

Keppra® extended release formulation - XR

Phase 3

Epilepsy

L-dopa

Phase 3

Idiopathic Parkinson's Disease

Secukinumab

Phase 3

Chronic Plaque Psoriasis

Lasosamide Oral Solution

Phase 3

Epilepsy

SPM 962

Phase 3

Parkinson's Disease

Lacosamide Tablet

Phase 3

Epilepsy

levocetirizine dihydrochloride

Phase 3

Rhinitis

Risankizumab

Phase 3

Psoriatic Arthritis

Ketotifen

Phase 3

Rhinitis, Allergic, Perennial

Lacosamide

Phase 3

Epilepsy

Bimekizumab

Phase 3

Chronic Plaque Psoriasis

SPM 927

Phase 3

Partial Seizures With or Without Secondary Generalization

BRV 2.5 mg

Phase 3

Unverricht-Lundborg Disease

Ustekinumab

Phase 3

Chronic Plaque Psoriasis

Epratuzumab

Phase 3

Systemic Lupus Erythematosus

Brivaracetam tablets

Phase 3

Epilepsy

certolizumab pegol (CDP870, CZP)

Phase 3

Crohn Disease

Keppra XR

Phase 3

Epilepsy

Lacosamide (200 mg/20 mL)

Phase 3

Epilepsy

Cimzia

Phase 3

Crohn Disease

Certolizumab Pegol + Methotrexate (MTX)

Phase 3

Rheumatoid Arthritis

Alprostadil (Prostaglandin E1)

Phase 3

Stage II Peripheral Arterial Occlusive Disease

Lacosamide 50 mg

Phase 3

Epilepsy

Kemstro

Phase 3

Multiple Sclerosis

Carbamazepine

Phase 3

Epilepsy

Certolizumab Pegol (CZP) 200 mg

Phase 3

Rheumatoid Arthritis

fenfluramine

Phase 3

Dravet Syndrome

Brivaracetam 2.5 mg

Phase 3

Epilepsy

Antiepileptic drugs with market authorization available per country

Phase 3

Epilepsy

Rozanolixizumab

Phase 3

Generalized Myasthenia Gravis

Romosozumab

Phase 3

Osteoporosis

zilucoplan (RA101495)

Phase 3

Generalized Myasthenia Gravis

Etanercept

Phase 3

Psoriasis

Certolizumab pegol (CZP)

Phase 3

Crohn's Disease

DZP

Phase 3

Systemic Lupus Erythematosus

Methotrexate

Phase 3

Rheumatoid Arthritis

Somatostatin UCB (drug)

Phase 2

Peptic Ulcer

Rotigotine Nasal Spray

Phase 2

Restless Legs Syndrome

UCB0022

Phase 2

Parkinson Disease

UCB7665

Phase 2

Thrombocytopenia

SPM927/Lacosamide

Phase 2

Painful Diabetic Neuropathy

Carboplatin

Phase 2

Carcinoma

Dapirolizumab pegol (DZP)

Phase 2

Systemic Lupus Erythematosus (SLE)

Seletracetam (ucb 44212)

Phase 2

Epilepsy, Partial

UCB0599

Phase 2

Early-stage Parkinson's Disease

Padsevonil

Phase 2

Drug-resistant Epilepsy

Levocetirizine oral solution

Phase 2

Allergic Rhinitis

Lorazepam

Phase 2

Epilepsy

CDP323

Phase 2

Relapsing Multiple Sclerosis

UCB9741

Phase 2

Atopic Dermatitis

CDP6038

Phase 2

Arthritis

Levocetirizine drops

Phase 2

Rhinitis

UCB1381

Phase 2

Atopic Dermatitis

Tocilizumab (Actemra or RoActemra)

Phase 2

Rheumatoid Arthritis

ginisortamab

Phase 2

Advanced Solid Tumors

Bepranemab

Phase 2

Alzheimer's Disease

Seletracetam (UCB44212)

Phase 2

Epilepsy, Partial

Epratuzumab 400 mg

Phase 2

Systemic Lupus Erythematosus

doxecitine and doxribtimine

Phase 2

Thymidine Kinase 2 Deficiency

Olokizumab 60 mg

Phase 2

Rheumatoid Arthritis

UCB0942

Phase 2

Highly Drug-resistant Focal Epilepsy

Certolizumab Pegol (Cimzia®)

Phase 2

Psoriasis

SPM 936

Phase 2

Idiopathic Restless Leg Syndrome

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals
UCBJY News